Ask about this productRelated genes to: CD205 antibody
- Gene:
- LY75 NIH gene
- Name:
- lymphocyte antigen 75
- Previous symbol:
- -
- Synonyms:
- DEC-205, CLEC13B, CD205
- Chromosome:
- 2q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-12-17
- Date modifiied:
- 2016-10-05
Related products to: CD205 antibody
Related articles to: CD205 antibody
- Lymphoma is a common hematologic malignancy with limited treatment options. The research objective was to ascertain plasma proteins that could be targeted for lymphoma treatment. - Source: PubMed
Publication date: 2025/11/12
Guo QianqianShang JuanjuanLiu BingyuDing MeiHan YangLuo YingshuWang XinHu Shunfeng - Despite genome-wide association studies having revealed risk loci for membranous nephropathy (MN), the functional mechanisms linking genetic variants to disease pathogenesis remain poorly understood. - Source: PubMed
Publication date: 2025/10/25
Chen QingsongWang GangZhao RuoHu QiyuanLi JiayunWang YutingRan JingyangHuang QiYu GuiquanLuo YanjiaLiao Xiaohui - Accurate risk assessment of local recurrences or metastases is essential for melanoma treatment, but current clinical parameters are suboptimal. Therefore, we conducted a comprehensive DNA methylation analysis to identify prognostic markers that could improve risk prediction in patients with melanoma. We integrated methyl-binding domain sequencing, RNA sequencing, Infinium HumanMethylation450 analyses, and The Cancer Genome Atlas data to identify potential prognostic DNA methylation markers. Validation was performed using methylation-specific PCR in 2 independent melanoma cohorts as well as an in silico validation using The Cancer Genome Atlas data. Cox proportional hazards models and backward stepwise elimination determined the prognostic value of candidate markers. LY75 promoter methylation, Breslow thickness, and metastatic disease at diagnosis were significant independent predictors of recurrence-free survival. LY75 promoter methylation was also found to be an independent predictor of metastatic disease development in patients with localized stage I/II melanoma specifically. This association was confirmed in a second validation cohort and The Cancer Genome Atlas melanoma dataset. LY75 promoter methylation identifies patients at high risk of recurrences or metastases, independent of conventional prognostic parameters. This marker could help refine patient selection for sentinel node biopsies, imaging, (neo)adjuvant treatment, and closer monitoring, ultimately leading to improved clinical outcomes. - Source: PubMed
Publication date: 2025/07/30
van den Hurk KarinLommen KimCoussement Louisvan den Kerkhof DaniqueBeckers MaraTrooskens GeertVan Neste LeanderOosterhof Marloesvan Doorn Remcovan den Oord Joost JKerkhofs ThomasAarts Maureen J BRamaekers BramJoore ManuelaWinnepenninckx Véronique J LVan Criekinge WimGallagher WilliamDe Meyer TimSmits Kim Mvan Engeland Manon - Proteolytic cleavage by furin-like proteases is a crucial first step in the posttranslational modification of various glycoproteins found in enveloped emerging viruses, such as SARS-CoV-2 and highly pathogenic avian influenza A viruses (IAV). Here, we explored the capacity of host cell proteins identified by cell surface proximity ligation to limit the proteolytic cleavage of the SARS-CoV-2 spike and the IAV H5N1 hemagglutinin (HA). When co-expressed with recombinant SARS-CoV-2 spike protein, Prom1, Axl, and Ly75 suppress its proteolytic cleavage, whereas cleavage of HA was only reduced by Prom1. Co-immunoprecipitation assays suggest that Axl and Prom1 may form a complex with furin. Alteration of Prom1, Axl and Ly75 expression levels in Calu3 cells affected entry of SARS-CoV-2 S pseudotyped VLP and to a lesser extent, SARS-CoV-2 virions. In contrast, Prom1 levels did not affect entry of H5N1 VLPs or H5N1 virions. Our data highlight the differential capacity of SARS-CoV-2 and IAV H5N1 to cope with newly identified host restriction factors of furin activity. - Source: PubMed
Publication date: 2025/07/15
Williams NathaliaChabert MehdiBesomi AliciaSilva FiloSobiech KarolinaSchmolke Mirco - The treatment of papillary thyroid carcinoma (PTC) presents ongoing challenges, underscoring the need for novel therapeutic targets. - Source: PubMed
Publication date: 2025/05/08
Xu JianxiongGao Chen